Companies › CAMP4 Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CMP-CPS-001 Antisense oligonucleotide targeting OTC (ornithine transcarbamylase) | OTC | Phase 1 | Healthy Volunteers | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06247670 | CMP-CPS-001 | Phase 1 | Healthy Volunteers | Metabolic and endocrine | Dec 2027 |
Cash of $125m on 2026-09-30; operating cash outflow about $43m a year; runway about 35 months at that burn, to Aug 2029
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.